- What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
- Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
- Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics Earns 2024 Great Place To Work® Certification™
- Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
- Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
- Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
- Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
- QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
- Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.26 |
---|---|
High | 27.96 |
Low | 26.24 |
Bid | 27.35 |
Offer | 29.78 |
Previous close | 25.97 |
Average volume | 822.75k |
---|---|
Shares outstanding | 90.51m |
Free float | 88.53m |
P/E (TTM) | -- |
Market cap | 2.45bn USD |
EPS (TTM) | -2.82 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼